| 產(chǎn)品名稱(chēng) |
203-7D10 |
| 商品貨號(hào) |
B163637 |
| Organism |
Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension but many cells attach |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
Cancer |
| Applications |
Animals were immunized with a synthetic polypeptide with the sequence (C)GSSKSKPKDPSQRRHS corresponding to peptides 2 to 17 of the v-src oncogene. In immunoblot screening, the antibody detects a 60 kd protein in the src transformed T2 cell line. A number of additional proteins are also detected in cell lines and embryo tissues including a 50 kd protein in the urine of cancer patients as well as the amniotic fluid of pregnant patients. |
| Derivation |
Spleen cells were fused with Sp2/0 myeloma cells. |
| Clinical Data |
A number of additional proteins are also detected in cell lines and embryo tissues including a 50 kd protein in the urine of cancer patients as well as the amniotic fluid of pregnant patients. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against a synthetic v-src oncogene peptide |
| Cellular Products |
immunoglobulin; monoclonal antibody; against a synthetic v-src oncogene peptide |
| Comments |
Animals were immunized with a synthetic polypeptide with the sequence (C)GSSKSKPKDPSQRRHS corresponding to peptides 2 to 17 of the v-src oncogene. Spleen cells were fused with Sp2/0 myeloma cells. In immunoblot screening, the antibody detects a 60 kd protein in the src transformed T2 cell line. A number of additional proteins are also detected in cell lines and embryo tissues including a 50 kd protein in the urine of cancer patients as well as the amniotic fluid of pregnant patients. The reactivity of the antibody with the src peptide (2-17) was confirmed by ELISA. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing |
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 X 10 exp5 viable cells/ml. Maintain cell density between 2 X 10 exp5 and 2 X 10 exp6 viable cells/ml. |
| Cryopreservation |
culture medium 95%; DMSO, 5% |
| Culture Conditions |
Temperature: 37.0°C |
| Isotype |
IgG2a; IgG2b |
| Name of Depositor |
National Cancer Institute |
| Deposited As |
mouse (B cell); mouse (myeloma) |
| References |
Niman HL, Lerner RA. Polypeptide-induced monoclonal receptors to protein ligands. US Patent 5,015,571 dated May 14 1991
|
